

DAFTAR PUSTAKA

- Abudawood M. Diabetes and cancer: A comprehensive review. *J Res Med Sci.* 2019;24(1):94. doi:10.4103/jrms.JRMS_242_19
- Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J. K., Dewanjee, S., Vallamkondu, J., & Pérez De La Lastra, J. M. (2023). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. *Genes & Diseases*, 10(4), 1367–1401. <https://doi.org/10.1016/j.gendis.2022.02.007>
- Anderson, P. O., Knoben, J. E., & Troutman, W. G. (Ed.). (2002). *Handbook of clinical drug data* (10th ed). McGraw-Hill Medical Pub. Division.
- American Cancer Society, 2021, *Understanding Lab Test Result*, diakses pada 15 Juni 2022, <https://www.cancer.org/content/dam/CRC/PDF/Public/7174.pdf>.
- American Cancer Society, 2021, *Low White Blood Cell Counts*, diakses pada 16 Juni 2022, <https://www.cancer.org/content/dam/CRC/PDF/Public/9468.00.pdf>
- Ba, Y., Shi, Yuankai, Jiang, W., Feng, J., Cheng, Y., Xiao, L., dkk., 2020. Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. *Cancer Biol Med*, 17: 896–909.
- Bongiovanni, A., Recine, F., Fausti, V., Rossi, B., Mercatali, L., Liverani, C., dkk., 2019. Clinical role of filgrastim in the management of patients at risk of prolonged severe neutropenia: An evidence-based review. *Int J Clin Pract*, 73: 1-8.
- Budiana, I.N.G. dan Febiani, M., 2017. Febrile Neutropenia pada Pasien Pascakemoterapi. *Indonesian Journal of Cancer*, 11: 77.
- Choi YW, Jeong SH, Ahn MS, et al. Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. *J Korean Med Sci.* 2014;29(11):1493. doi:10.3346/jkms.2014.29.11.1493
- Cortés de Miguel, S., Calleja-Hernández, M.Á., Menjón-Beltrán, S., dan Vallejo-Rodríguez, I., 2015. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. *Supportive Care in Cancer*, 23: 547–559.
- Danasasmita GW, Chen LK, Sinto R, Nugroho P. Profil Pasien Demam Neutropenia Tidak Terkait Kemoterapi di Rumah Sakit Umum Pusat Nasional Dr. Cipto

doi:10.7454/jpdi.v7i4.384

DiPiro JT, Gary C.Y, Stuart T.H, Thomas D.N, Vicki L.E, L. Michael Posey, Pharmacotherapy: A Pathophysiologic Approach, 10th ed. New York: McGraw-Hill Education

Donadieu, J., Beaupain, B., Bou Mitri, F., Sicre De Fontbrune, F., Moushous, D., Lamy, T., Moignet Autrel, A., Gouache, E., Pasquet, M., & Bellanne-Chantelot, C. (2020). Lenograstim and Filgrastim Have a Similar Efficacy and Safety Profile in the Treatment of Chronic Neutropenia. A Study for the French SCN Registry: *Blood*, 136(Supplement 1), 17–18. <https://doi.org/10.1182/blood-2020-138476>

Fk, T., Jg, T., dan Lc, R., 2017. PERSPECTIVES IN FEBRILE NEUTROPENIA, *AJMJ*, 5 : 9-13.

Frampton, J.E., Lee, C.R., dan Faulds, D., 1994. Filgrastim: A Review of its Pharmacological Properties and Therapeutic Efficacy in Neutropenia. *Drugs*, 48: 731–760.

Gabay M., Tanzi, M., 2010. Guideline for Management Febril Neutrophenia, *Clinical Oncologi News Special*, 1 : 115-122.

Globocan, 2020, Cancer Fact Sheets for Indonesia, diakses pada 1 Maret 2022 <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>

Goodman, C. C., Fuller, K. S., 2020, Pathology: Implications for the Physical Therapist Fifth Edition, In Saunders *Elsevier*.

Hima, N.A., Andrajati, R., dan Radji, M., 2021. Kejadian Demam Neutropenia pada Pasien Kanker Payudara setelah Menerima Regimen Kemoterapi TAC-G-CSF dan FAC di RSUP Dr. Hasan Sadikin Bandung. *Indonesian Journal of Clinical Pharmacy*, 10: 1.

Innocenti R, Rigacci L, Restelli U, dkk., 2018, Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. *J Blood Med.* Volume 10:21-27. doi:10.2147/JBM.S186786

Joudeh N, Sawafta E, Abu Taha A, dkk., 2023, Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country.

Justiz Vaillant AA., Zito PM., 2021, Neutropenia. Diakses pada 9 Juni 2022, <https://www.ncbi.nlm.nih.gov/books/NBK507702/>

Kalbemed, 2023, Produk : Leucogen, diakses pada 23 September 2023, <https://www.kalbemed.com/product/id/248>

Karimi F, Ashrafi F, Moghaddas A, Derakhshandeh A., 2018, Management of febrile neutropenia: A description of clinical and microbiological findings by focusing on risk factors and pitfalls. *J Res Pharm Pract.* 7(3):147. doi:10.4103/jrpp.JRPP_18_16

Kasi, P.M. dan Grothey, A., 2018. Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. *Drugs*, **78**: 737–745.

Keating, G.M., 2011. Lenograstim: A Review of its Use in Chemotherapy-Induced Neutropenia, for Acceleration of Neutrophil Recovery Following Haematopoietic Stem Cell Transplantation and in Peripheral Blood Stem Cell Mobilization. *Drugs*, **71**: 679–707.

Kenar G, Köksoy EB, Ürün Y, Utkan G., 2020. Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer. *Support Care Cancer.* 28(11):5235-5242. doi:10.1007/s00520-020-05336-w

Kemenkes RI, 2019, Infodatin: Beban Kanker di Indonesia, diakses pada 1 Maret 2022, <https://pusdatin.kemkes.go.id/article/view/20112600001/beban-kanker-di-indonesia.html>

Kemenkes RI, 2020, Formularium Nasional, Jakarta : Kemenkes RI.

Kim, H.S., Lee, S.Y., Kim, J.W., Choi, Y.J., Park, I.H., Lee, K.S., dkk., 2016. Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea. *Oncology*, **91**: 274–282.

Kim YR, Kim SJ, Park Y, dkk., 2021, Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis. *Korean J Intern Med.* ;36(5):1181-1189. doi:10.3904/kjim.2020.206

- Kholis, F.N., 2017. Penilaian Risiko Infeksi Dengan Skor Mascc Pada Penderita Demam Neutropenia Di Rumah Sakit Dr. Kariadi Dan Telogorejo Semarang. *Media Medika Muda*, **2** : 8.
- Klustersky, J., de Naurois, J., Rolston, K., Rapoport, B., Maschmeyer, G., Aapro, M., dkk., 2016. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. *Annals of Oncology*, **27**: v111–v118.
- Kleinhendler, E., Cohen, M.J., Moses, A.E., Paltiel, O., Strahilevitz, J., dan Cahan, A., 2018. Empiric antibiotic protocols for cancer patients with neutropenia: a single–center study of treatment efficacy and mortality in patients with bacteremia. *International Journal of Antimicrobial Agents*, **51**: 71–76.
- Lacy, C.F, Armstrong, L.L., Goldman, M.P, Lance, L.L., 2018. Drug Information Handbook 28th Edition, Lexi-comp & AphA, Ohio.
- Laribi K, Badinand D, Janoray P, dkk., 2019,. Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study. *Support Care Cancer*. 2019;27(11):4283-4292. doi:10.1007/s00520-019-04725-0
- Lazarchick, J., 2012. Update on anemia and neutropenia in copper deficiency: *Current Opinion in Hematology*, **19**: 58–60.
- Lazarus, H.M., Ragsdale, C.E., Gale, R.P., dan Lyman, G.H., 2021. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time? *Frontiers in Immunology*, **12**: 706186.
- Liu, L., Liu, Y., Yan, X., Zhou, C., & Xiong, X., 2020, The role of granulocyte colony-stimulating factor in breast cancer development: A review, *Molecular Medicine Reports*. <https://doi.org/10.3892/mmr.2020.11017>
- Lyman, G.H., Abella, E., dan Pettengell, R., 2014. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. *Crit Rev in Oncol/Hematol*, **90**: 190–199.
- Ma RM, Chen CZ, Zhang W, You J, Huang DP, Guo GL. 2016, Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer. *Medicine (Baltimore)*. 2016;95(13):e3240. doi:10.1097/MD.0000000000003240

Mehta, H.M., Malandra, M., dan Corey, S.J., 2015. G-CSF and GM-CSF in Neutropenia.

J Immunol, **195**: 1341–1349.

Melhem, M., Delor, I., Pérez-Ruixo JJ., Harrold J., Chow A, Wu L, Jacqmin P., dkk, 2018. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. *Br J Clin Pharmacol*, 84 (5) :911-925.

National Cancer Institute, 2022, *Understanding Cancer Term*, diakses pada 10 Juni 2022, <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cancer>

National Cancer Institute, 2022, *Dictionary Cancer Term : ANC*, diakses pada 15 Juni 2022, <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/anc>

NCCN, 2021, *Anemia and Neutrophenia*, diakses pada 18 Juni 2022, <https://www.nccn.org/patients/guidelines/content/PDF/anemia-patient-guideline.pdf>

National Institute of Aging, di akses pada 17 Mei 2023 Pukul 21.00

<https://www.nia.nih.gov/health/what-menopause> - U.S. Department of Health & Human Services (HHS)

Palmblad, J., Dufour, C., dan Papadaki, H.A., 2014. How we diagnose neutropenia in the adult and elderly patient. *Haematologica*, **99**: 1130–1133.

Philip ML, Saj N, Sebastian AM, Mateti UV, Shetty V., 2019, Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients. *Indian J Med Paediatr Oncol*. 2019;40(02):249-256. doi:10.4103/ijmpo.ijmpo_31_18

Pratiwi M, Sutrisna EM., 2021. Evaluasi Ketepatan Pemberian Antibiotik Empirik Pada Pasien Demam Neutropenia Akibat Kemoterapi Di RSUP Dr Kariadi Semarang. *Lambung Farm J Ilmu Kefarmasian*. 2021;2(2):62. doi:10.31764/lf.v2i2.5486

Rahi, V., Jamwal, S., dan Kumar, P., 2021. Neuroprotection through G-CSF: recent advances and future viewpoints. *Pharmacological Reports*, **73**: 372–385.

Sanofi, 2023, Pruduk : Granocyte, diakses pada 23 September 2023 <https://www.sanofi.co.id/in/kesehatan-anda/obat-resep/onkologi>

- Schirmacher, V., 2019. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). *Int J Oncol*, 13.
- Setiani, D., 2015. Perbandingan Efektivitas Produk Filgrastim pada Pasien Keganasan Limfoma yang Menerima Kemoterapi di RSUP dr. Sardjito Yogyakarta. *Jurnal Farmasi (Journal of Pharmacy)*, 4: 9.
- Setiawan, S.D., 2015. The Effect of Chemotherapy in Cancer Patient to Anxiety, *J Majority*, 4 : 94-99
- Shah, S.C., Kayamba, V., Peek, R.M., dan Heimburger, D., 2019. Cancer Control in Low- and Middle-Income Countries: Is It Time to Consider Screening? *Journal of Global Oncology*, 1–8.
- Shahid RK, Ahmed S, Le D, Yadav S. Diabetes and Cancer: Risk, Challenges, Management and Outcomes. *Cancers*. 2021;13(22):5735. doi:10.3390/cancers13225735
- Sjakti, H.A., 2010. Penggunaan Granulocyte Colony-Stimulating Factor pada Pasien Tumor Padat yang. *Sari Pediatri*, 11: 6.
- Severe Chronic Neutropenia International Registry, 2022, *Derermining ANC (Absolute Neutrophil Count)*, diakses pada 16 Juni 2022, <https://www.scnir-neutropenia.uw.edu/calculating-an-absolute-neutrophil-count>
- Sourgens, H., & Lefrère, F. (2011). A systematic review of available clinical evidence – filgrastim compared with lenograstim. *Int. Journal of Clinical Pharmacology and Therapeutics*, 49(08), 510–518. <https://doi.org/10.5414/CP201537>
- Street, W., 2020. Breast Cancer Facts & Figures 2019-2020 : About Breast Cancer. *American Cancer Society*, 44.
- Theyab, A., Algahtani, M., Alsharif, K.F., Hawsawi, Y.M., Alghamdi, Abdulaziz, Alghamdi, Adel, dkk., 2021. New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. *Hematology*, 26: 628–636.
- Tralongo, A.C., Antonuzzo, A., Pronzato, P., Sbrana, A., Turrini, M., Zoratto, F., dkk., 2020. Management of chemotherapy-induced neutropenia in patients with cancer:

2019 guidelines of the Italian Medical Oncology Association (AIOM). *Tumori Journal*, **106**: 273–280.

Treffers LW, Hiemstra IH, Kuijpers TW, Berg TK, Matlung HL. 2016, Neutrophils in cancer. *Immunol Rev*. 2016;273(1):312-328. doi:10.1111/imr.12444

Utomo, A., Widyati, W., dan Susilo, D.H., 2020. Efektivitas Profilaksis Primer Filgrastim Pada Pasien Kanker Payudara terhadap Insiden Neutropenia. *MPI (Media Pharmaceutica Indonesiana)*, **3**: 52–59.

Wenzel UO, Ehmke H, Bode M., 2021, Immune mechanisms in arterial hypertension. Recent advances. *Cell Tissue Res*. 2021;385(2):393-404. doi:10.1007/s00441-020-03409-0

Weycker D, Barron R, Kartashov A, Legg J, Lyman GH., 2014, Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. *Journal of Oncology Pharmacy Practice*. 2014;20(3):190-198. doi:10.1177/1078155213492450

WHO : menopause, 2022 diakses pada 17 Mei 2023 Pukul 21.00
<https://www.who.int/news-room/fact-sheets/detail/menopause>

Z L, W YQ, Y X, dkk., 2021, Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis. *J Ovarian Res*. 2021;14(1). doi:10.1186/s13048-020-00758-w

Zhu X, Wu S.. 2022, Risks and management of hypertension in cancer patients undergoing targeted therapy: a review. *Clin Hypertens*. 2022;28(1):14. doi:10.1186/s40885-022-00197-3